펜실베이니아의 전립선암 임상 시험
전립선암 관련 연구 64개가 펜실베이니아 내 여러 지역에서 참여자를 모집하고 있습니다.
펜실베이니아의 도시
- Philadelphia연구 44개
- Pittsburgh연구 23개
- Harrisburg연구 8개
- Erie연구 5개
- York연구 5개
- Scranton연구 5개
- Hazleton연구 4개
- Reading연구 4개
- Lancaster연구 4개
- Chambersburg연구 3개
- Allentown연구 3개
공식 연구 텍스트(영어)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Pocono Medical Center, East Stroudsburg
- 외 8개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT03866382A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia
피험자 모집 중1상
18세 이상 · 남성 · 2026. 9. 28. 업데이트됨 · NCT06095089DESTINY-PANTUMOUR04
- Research Site, Philadelphia
피험자 모집 중관찰 연구
18세 ~ 130세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07124000A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- MidLantic urology ( Site 0022), Bala-Cynwyd
- Fox Chase Cancer Center ( Site 0076), Philadelphia
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06136650This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- MidLantic urology, Bala-Cynwyd
- The Centers for Advanced Urology d/b/a Keystone Urology Specialist, Lancaster
피험자 모집 중3상
18세 이상 · 남성 · 2026. 9. 24. 업데이트됨 · NCT07028853A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- University of Pittsburgh Medical Center, Pittsburgh
피험자 모집 중3상
18세 이상 · 남성 · 2026. 9. 22. 업데이트됨 · NCT07213674Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Fox Chase Cancer Center, Philadelphia
피험자 모집 중2/3상
18세 ~ 100세 · 남성 · 2026. 9. 22. 업데이트됨 · NCT06780670A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- University of Pittsburgh Medical Center, Pittsburgh
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07114601A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Hershey
- Research Site, Lancaster
- Research Site, Pittsburgh
피험자 모집 중3상
18세 이상 · 남성 · 2026. 9. 18. 업데이트됨 · NCT06952803Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
- Philadelphia MultiService Center, Philadelphia, PA, Philadelphia
피험자 모집 중2상
18세 이상 · 남성 · 2026. 9. 17. 업데이트됨 · NCT04038502A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Perelman Center for Advanced Medicine ( Site 0067), Philadelphia
- Abramson Cancer Center - Penn Medicine ( Site 0079), Philadelphia
피험자 모집 중3상
18세 이상 · 남성 · 2026. 9. 17. 업데이트됨 · NCT06925737First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
- GSK Investigational Site, Philadelphia
피험자 모집 중1/2상
18세 이상 · 남성 · 2026. 9. 16. 업데이트됨 · NCT07332455Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
- Thomas Jefferson University, Philadelphia
- University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh
피험자 모집 중1상
18세 이상 · 남성 · 2026. 9. 15. 업데이트됨 · NCT07493512The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT04585750Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- MidLantic Urology, Bala-Cynwyd
피험자 모집 중
18세 이상 · 남성 · 2026. 9. 14. 업데이트됨 · NCT06511141Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- UPMC-Heritage Valley Health System Beaver, Beaver
- Carlisle Regional Cancer Center, Carlisle
- Christiana Care Health System-Concord Health Center, Chadds Ford
- 외 24개
피험자 모집 중3상
18세 이상 · 남성 · 2026. 9. 10. 업데이트됨 · NCT05946213Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
- Wellspan, Chambersburg
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT06138067Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Saint Vincent Hospital, Erie
- Jefferson Hospital, Jefferson Hills
- Forbes Hospital, Monroeville
- 외 8개
피험자 모집 중3상
18세 이상 · 남성 · 2026. 9. 2. 업데이트됨 · NCT06931340Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- 외 7개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT05334069A Study of Tarlatamab for People With Prostate Cancer
- Thomas Jefferson University Hospital, Philadelphia
피험자 모집 중2상
18세 이상 · 남성 · 2026. 8. 31. 업데이트됨 · NCT07111507Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
- Penn State Cancer Institute, Hershey
피험자 모집 중1/2상
40세 이상 · 남성 · 2026. 8. 31. 업데이트됨 · NCT06600698AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, Pittsburgh
피험자 모집 중3상
18세 이상 · 남성 · 2026. 8. 26. 업데이트됨 · NCT07611110Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- Lancaster Urology, Lancaster
피험자 모집 중2상
18세 이상 · 남성 · 2026. 8. 24. 업데이트됨 · NCT07745361Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Thomas Jefferson University, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
피험자 모집 중1상
18세 이상 · 남성 · 2026. 8. 21. 업데이트됨 · NCT04221542A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
- Abramson Cancer Center of the University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia
피험자 모집 중2상
18세 이상 · 남성 · 2026. 8. 21. 업데이트됨 · NCT06844383Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- UPMC Altoona, Altoona
- UPMC-Heritage Valley Health System Beaver, Beaver
- Carlisle Regional Cancer Center, Carlisle
- 외 26개
피험자 모집 중3상
18세 이상 · 남성 · 2026. 8. 19. 업데이트됨 · NCT04423211FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT05919264Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Penn State Milton S. Hershey Medical Center, Hershey
- Thomas Jefferson University Honickman Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
피험자 모집 중1상
18세 ~ 100세 · 남성 · 2026. 8. 13. 업데이트됨 · NCT05519449Distance-Based Exercise to Preserve Function and Prevent Disability
- UPMC Hillman Cancer Center at Butler Health System, Butler
- IRMC Cancer Center, Indiana
- UPMC Hillman Cancer Center - New Castle, New Castle
- 외 2개
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 8. 5. 업데이트됨 · NCT07059884Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
- Thomas Jefferson University, Philadelphia
피험자 모집 중1상
18세 이상 · 남성 · 2026. 7. 31. 업데이트됨 · NCT06613100Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #109, Philadelphia
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 23. 업데이트됨 · NCT06545942PSMA PET Combined With MRI for the Detection of PCa
- MidLantic Urology, Philadelphia
피험자 모집 중3상건강한 지원자 환영
18세 이상 · 남성 · 2026. 7. 23. 업데이트됨 · NCT07052214Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Christiana Care Health System-Concord Health Center, Chadds Ford
- Geisinger Medical Center, Danville
- Geisinger Cancer Center Dickson City, Dickson City
- 외 6개
피험자 모집 중3상
18세 이상 · 남성 · 2026. 7. 14. 업데이트됨 · NCT06592924Study of ORIC-944 in Patients With Metastatic Prostate Cancer
- MidLantic Urology, Bala-Cynwyd
- Keystone Urology Specialists, Lancaster
피험자 모집 중1상
18세 이상 · 남성 · 2026. 7. 9. 업데이트됨 · NCT05413421Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
- Thomas Jefferson University, Philadelphia
- University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh
피험자 모집 중1상
18세 이상 · 남성 · 2026. 7. 2. 업데이트됨 · NCT07140900A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
- Thomas Jefferson University Hospital, Philadelphia
피험자 모집 중1/2상
18세 이상 · 남성 · 2026. 6. 25. 업데이트됨 · NCT06457919Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia
피험자 모집 중2상
18세 이상 · 남성 · 2026. 6. 15. 업데이트됨 · NCT05422911Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- University of Pittsburg Medical Center (UPCM), Pittsburgh
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 11. 업데이트됨 · NCT05283330Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
- UPMC Hillman Cancer Center, Pittsburgh
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 8. 업데이트됨 · NCT04890613Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
- Univ of Pittsburgh Medical Center, Pittsburgh
피험자 모집 중4상
18세 ~ 100세 · 남성 · 2026. 6. 4. 업데이트됨 · NCT05803941ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.